These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12645831

  • 1. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
    Wilson R, Langan C, Ball P, Bateman K, Pypstra R, Gemifloxacin 207 Clinical Study Group.
    Respir Med; 2003 Mar; 97(3):242-9. PubMed ID: 12645831
    [Abstract] [Full Text] [Related]

  • 2. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H, File TM, Mandell L, Ball P, Pypstra R, Thomas M, 185 Gemifloxacin Study Group.
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [Abstract] [Full Text] [Related]

  • 4. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.
    Zervos MJ, Heyder AM, Leroy B.
    J Int Med Res; 2003 Jan; 31(3):157-69. PubMed ID: 12870368
    [Abstract] [Full Text] [Related]

  • 5. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G, Barth J, Rubinstein E, Beckmann H, HAP study group.
    Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
    Sethi S, Fogarty C, Fulambarker A.
    Respir Med; 2004 Aug; 98(8):697-707. PubMed ID: 15303633
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
    Ball P, Wilson R, Mandell L, Brown J, Henkel T, 069 Clinical Study Group.
    J Chemother; 2001 Jun; 13(3):288-98. PubMed ID: 11450888
    [Abstract] [Full Text] [Related]

  • 8. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis.
    Weiss LR.
    Clin Ther; 2002 Sep; 24(9):1414-25. PubMed ID: 12380633
    [Abstract] [Full Text] [Related]

  • 9. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
    Wilson R, Schentag JJ, Ball P, Mandell L, 068 Study Group.
    Clin Ther; 2002 Apr; 24(4):639-52. PubMed ID: 12017408
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
    Ball P, File TM, Twynholm M, Henkel T.
    Int J Antimicrob Agents; 2001 Jul; 18(1):19-27. PubMed ID: 11463522
    [Abstract] [Full Text] [Related]

  • 11. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
    Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, Sagnier PP, MOSAIC Study Group.
    Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [Abstract] [Full Text] [Related]

  • 13. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.
    Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L.
    Antimicrob Agents Chemother; 2006 May; 50(5):1762-7. PubMed ID: 16641447
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).
    Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G, SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica.
    J Chemother; 2002 Dec; 14(6):597-608. PubMed ID: 12583552
    [Abstract] [Full Text] [Related]

  • 15. Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.
    Ferguson BJ, Anon J, Poole MD, Hendrick K, Gilson M, Seltzer EG, Gemifloxacin 186 Study Group.
    Otolaryngol Head Neck Surg; 2002 Jul; 127(1):1-6. PubMed ID: 12161723
    [Abstract] [Full Text] [Related]

  • 16. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P, File T, Feldman C.
    Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
    [Abstract] [Full Text] [Related]

  • 17. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 18. Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis.
    Vogel F, Droszcz W, Vondra V, Reisenberg K, Marr C, Staley H.
    J Antimicrob Chemother; 1997 Dec; 40(6):863-71. PubMed ID: 9462439
    [Abstract] [Full Text] [Related]

  • 19. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
    Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R.
    J Antimicrob Chemother; 1999 Apr; 43(4):529-39. PubMed ID: 10350383
    [Abstract] [Full Text] [Related]

  • 20. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
    File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C.
    J Chemother; 2000 Aug; 12(4):314-25. PubMed ID: 10949981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.